We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.9%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
-$238M
Cap. Flow
-$201M
Cap. Flow %
-14.89%
Top 10 Hldgs %
64.03%
Holding
94
New
18
Increased
13
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$50.4M
2
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$46.2M
3
AMGN icon
Amgen
AMGN
+$27.7M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.8M
5
NCNA
NuCana
NCNA
+$18.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$84.7M
2
GILD icon
Gilead Sciences
GILD
+$31M
3
CHRS icon
Coherus Oncology
CHRS
+$27.9M
4
AMRN
Amarin Corp
AMRN
+$24.2M
5
MRK icon
Merck
MRK
+$21.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTIC
26
DELISTED
Otonomy, Inc.
OTIC
$8.55M 0.63%
2,111,596
+460,185
+28% +$1.73M
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.07M 0.6%
+82,944
New +$9.55M
CHRS icon
28
Coherus Oncology
CHRS
$225M
$7.97M 0.59%
434,555
-1,498,666
-78% -$27.9M
CYTK icon
29
Cytokinetics
CYTK
$10.9B
$7.56M 0.56%
349,296
+189,079
+118% +$4.42M
ZYME icon
30
Zymeworks
ZYME
$1.69B
$7.08M 0.52%
151,902
-147,832
-49% -$5.08M
CYTK icon
31
PUT
Cytokinetics
CYTK
$10.9B
$7.04M 0.52%
+325,000
New +$7.6M
PTGX icon
32
Protagonist Therapeutics
PTGX
$8.72B
$6.99M 0.52%
357,769
+31,705
+10% +$595K
KURA icon
33
Kura Oncology
KURA
$901M
$6.9M 0.51%
225,259
-385,720
-63% -$8.52M
SUPN icon
34
Supernus Pharmaceuticals
SUPN
$2.73B
$6.88M 0.51%
330,295
-148,034
-31% -$3.36M
TGTX icon
35
TG Therapeutics
TGTX
$8.53B
$6.7M 0.5%
250,401
-445,989
-64% -$10.3M
XLRN
36
DELISTED
Acceleron Pharma
XLRN
$6.7M 0.5%
59,546
-157,844
-73% -$15.7M
RETA
37
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.68M 0.5%
68,615
+55,580
+426% +$6.94M
MYOK
38
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.68M 0.5%
48,998
-62,812
-56% -$6.68M
ARNA
39
DELISTED
Arena Pharmaceuticals Inc
ARNA
$6.59M 0.49%
88,150
+74,221
+533% +$4.95M
OVID icon
40
Ovid Therapeutics
OVID
$439M
$6.3M 0.47%
+1,097,621
New +$7.34M
MIRM icon
41
Mirum Pharmaceuticals
MIRM
$6.96B
$6.19M 0.46%
321,252
-220,449
-41% -$4.73M
RETA
42
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.84M 0.43%
+60,000
New +$7.5M
NVCR icon
43
CALL
NovoCure
NVCR
$1.97B
$5.57M 0.41%
50,000
– –
AMRN
44
Amarin Corp
AMRN
$290M
$4.93M 0.37%
58,529
-201,886
-78% -$24.2M
ACRS icon
45
Aclaris Therapeutics
ACRS
$750M
$4.91M 0.36%
1,911,573
– –
PBYI icon
46
Puma Biotechnology
PBYI
$407M
$4.8M 0.36%
475,982
-721,648
-60% -$7.35M
CHMA
47
DELISTED
Chiasma, Inc. Common Stock
CHMA
$4.5M 0.33%
1,047,354
-582,867
-36% -$2.79M
CCXI
48
DELISTED
ChemoCentryx, Inc.
CCXI
$4.45M 0.33%
81,235
-15,681
-16% -$844K
KNSA icon
49
Kiniksa Pharmaceuticals
KNSA
$4.89B
$4.24M 0.31%
276,628
-533,175
-66% -$10M
AGTC
50
DELISTED
Applied Genetic Technologies Corporation
AGTC
$4.01M 0.3%
825,071
-320,183
-28% -$1.75M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2020 Portfolio in Review

As of Q3 2020, Sofinnova Investments held 94 positions worth $1.35B, down 15% from $1.59B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sofinnova Investments withdrew a net $201M in Q3 2020, closing 26 positions and reducing 24 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $84.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Inozyme Pharma worth $53.3M.

  • Sofinnova Investments's largest Q3 2020 buy was Inozyme Pharma: 2,028,308 shares worth $53.3M.
  • Sofinnova Investments added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $19.8M increase.
  • Sofinnova Investments's biggest Q3 2020 reduction was Coherus Oncology, cutting an estimated $27.9M.
  • Sofinnova Investments fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $84.7M.
  • Sofinnova Investments's ten largest holdings make up 64% of its $1.35B portfolio in Q3 2020.
  • Sofinnova Investments opened 18 new positions and closed 26 in Q3 2020.
  • Sofinnova Investments's portfolio value fell 15% quarter-over-quarter to $1.35B.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.